SINGAPORE - The expansion of British drugmaker GSK’s facility in Tuas has earned the title of Singapore’s largest vaccine production site based on a cumulative investment of some $850 million ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

The drugmaker GSK plunged into the messenger RNA-based vaccine market Wednesday, announcing it will buy the rights to experimental influenza and Covid-19 mRNA vaccines from the biotech CureVac.

One example of this is GSK’s commitment to make its new malaria vaccine RTS,S affordable, the company planning to price it at £8.50 (10.42 US dollars) per child, based on demand of around 100 ...

GSK plc GSK announced that it has revised its collaboration deal with Chongqing Zhifei Biological Products (Zhifei), China's largest vaccine maker, to co-market its shingles vaccine Shingrix in ...

GSK GSK0.73%increase; green up pointing triangle cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations in the third quarter due ...

Nov 22 (Reuters) - GSK (GSK.L), opens new tab said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59 ...

GSK plc GSK announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of its meningococcal vaccine, Menveo (MenACWY) for active immunization in children ...

The European Commission (EC) has granted approval for a single-vial, fully liquid presentation of GSK's Menveo vaccine (MenACWY), designed to protect against invasive meningococcal disease (IMD ...

Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of ...